Clinical outcomes of lenalidomide, bortezomib, and dexamethasone in multiple myeloma patients.

ObjectiveTo investigate the clinical benefits of the combination therapy involving lenalidomide, bortezomib, and dexamethasone in treating multiple myeloma (MM).MethodsThis retrospective analysis included 182 patients with MM treated between January 2022 and June 2025. The patients were divided into a Lenalidomide group (n=93) and a control group (n=89). Before and after treatment, lactate dehydrogenase (LDH), β2-microglobulin, monoclonal protein, myeloma cells, serum calcium (CA), hemoglobin (Hb), free light chain (FLC), serum creatinine (Scr), Blood urea nitrogen (BUN), and Visual Analogue Scale (VAS) were compared between the groups. Adverse reactions were also recorded and compared. A nomogram model was established and evaluated using RStudio.ResultsThe Lenalidomide group showed a significantly better therapeutic response than the control group (P2-microglobulin, monoclonal protein, myeloma cells, CA, FLC-κ, FLC-λ, Scr and BUN in the nalidomide group were lower than those in the control group (all PPPConclusionLenalidomide, bortezomib, and dexamethasone, demonstrate significant clinical efficacy in treating multiple myeloma.